FHTX Earnings

Quarterly EPS
$-0.31
Q3 2024
$-0.31
Q4 2024
$-0.30
Q1 2025
$-0.28
Q2 2025
$-0.25
Q3 2025
$-0.34
Q4 2025
$-0.29
Q1 2026
$-0.10
Q2 2026
Latest Revenue16.1M
Latest Net Income-7191000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.1016.1M-7191000+112.7%+64.3%
Q1 2026-$0.293.3M-19875000-45.1%+3.3%
Q4 2025-$0.349.2M-21664000+223.8%-9.7%
Q3 2025-$0.258.2M-15849000+4.4%+19.4%
Q2 2025-$0.287.6M-17936000+9.7%+37.8%
Q1 2025-$0.306.0M-18834000+17.9%+49.2%
Q4 2024-$0.312.9M-19503000-50.5%+45.6%
Q3 2024-$0.317.8M-19122000-55.3%+8.8%
Q2 2024-$0.456.9M-22979000
Q1 2024-$0.595.0M-25016000
Q4 2023-$0.575.8M-24106000
Q3 2023-$0.3417.5M-14345000
Foghorn Therapeutics (FHTX) — Earnings